A year after the FDA rejected Cell Therapeutics Inc.'s (CTI) pixantrone application for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL), the Office of New Drugs (OND) has denied an appeal request from CTI, which claimed the drug showed efficacy.